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Summary We measured tumour cellular DNA in 102 patients entered into two phase III trials of
chemotherapy for end stage squamous carcinoma of the head and neck. The median survival of untreated
patients with aneuploid tumours was 55 days compared with 224 days for patients treated with cisplatinum.
This difference was highly significant. In contrast the median survival of untreated patients with diploid
tumours was 74 days compared with 118 days for treated patients. Although this difference is statistically
significant, the increased survival of 6 weeks is of no clinical benefit compared with the prolongation of
survival of 6 months in patients with aneuploid tumours. Multivariate analysis showed that the significant
predictors of survival were Karnofsky status, response to chemotherapy and ploidy.
The relationship of ploidy to prognosis in solid tumours has
been widely studied. In general patients with diploid tumours
have been found to have a more favourable prognosis than
those with aneuploid cancers (Cornelisse et al., 1987; Joensuu
et al., 1986; Zimmerman et al., 1987). Relatively few studies
of squamous cell carcinoma of the head and neck have been
reported and not all agree that aneuploidy confers a poor
prognosis (Goldsmith et al., 1987). However, recent studies
of resectable squamous cell carcinoma suggest a poor out-
come for those with an aneuploid DNA content (Kokal et
al., 1988).
There is preliminary evidence that DNA ploidy may also
predict response to cytostatic therapy. In certain leukaemias
treated by chemotherapy, the aneuploid tumours are the
most responsive (Barlogie et al., 1987). In order to test this
hypothesis on solid tumours we have assessed the effect of
ploidy in cancers from patients entered into two phase III
prospective randomised trials of chemotherapy for end stage
squamous carcinoma of the head and neck (Morton et al.,
1985; Allison et al., 1989).
Entry into these trials was confined to patients with locally
advanced or recurrent squamous cell cancers unsuitable for
radiotherapy or surgery who were then randomised either to
no further treatment or to various chemotherapy regimes. Of
these, single agent cisplatinum produced the greatest prolong-
ation of survival. Therefore in this investigation we have
determined the tumour DNA content by flow cytometric
analysis from patients in these trials who were randomised to
receive cisplatinum or who acted as untreated controls.
Patients and methods
Selection ofpatients
Patients were recruited into two phase III trials of end stage
squamous carcinoma of the head and neck between 1982 and
1987. A total of 315 patients with locally advanced or recur-
rent squamous cell cancer presenting to the Mersey Regional
Head and Neck Unit were randomised prospectively to
receive either chemotherapy or to act as untreated controls.
For this investigation 88 patients randomised to receive cis-
platinum and 95 who received no further treatment were
selected. Only the 102 patients for whom archival paraffin
embedded tissue from the last biopsy or operative specimen
was available were studied.
Dosage and administration
Cisplatinum was administered as an infusion at a dosage of
100 mg m 2 body surface area if the creatinine clearance
exceeded 60 ml min-' and at halfthat dosage if the creatinine
clearance lay between 50 and 60 ml min-'. This treatment
was given at monthly intervals until either the tumour pro-
gressed, toxicity became unacceptable or the patient refused
further treatment.
Patient assessment
The WHO definition of response of the tumour was used. A
partial response was defined as a reduction of at least 50% in
the product of two perpendicular diameters of all assessable
lesions and a complete response was defined as the absence
of clinically detectable disease (Miller et al., 1981).
Flow cytometric analysis
Thick sections were examined by flow cytometry. Con-
secutive 5 tim sections were stained by haematoxylin and
eosin to confirm the presence of tumour in all samples
studied. Nuclei were extracted from formalin fixed paraffin
embedded tissue (Hedley et al., 1983). Multiple 50 .Lm sec-
tions were dewaxed in xylene and rehydrated through 0.5%
pepsin in 0.9% NaCl at pH 1.5 for 30 min at 37C. The
digest was then centrifuged, washed and resuspended. After
resuspension in 1 ml of phosphate buffered saline the digest
was syringed 3 or 4 times to disaggregate nuclear clumps and
then filtered through 40 lm nylon mesh.
Nuclear concentrations were adjusted when necessary to
give a final concentration of 10 nuclei per ml. DNA was
analysed by a FACS flow cytometer (Becton Dickinson Sun-
nyvale, CA, USA). Where possible fluorescence from 100,000
nuclei was recorded, a minimum of 10,000 being required to
give interpretable histograms. The use of paraffin sections
containing normal cells acted as an internal control, enabling
tumour cells with more or less than 2 c DNA to be detected.
Histograms were classified as aneuploid or diploid, and only
those with a coefficient of variation of less than 8% were
accepted. Tetraploid tumours, especially if they represent a
small fraction of the whole section may be difficult to detect
as those tumours cells in the GO and Gl phases of the cell
cycle have the same DNA content as normal cells in G2 and
M phase. In these cases a 4 c peak representing more than
20% of the whole cell population was designated aneuploid
as it was unlikely that normal cells would have such a high
G2/M peak.
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Statistical analysis
Qualitative data such as response rates are displayed by
contingency tables and analysed by the X2 method. Survival
rates are shown by the Kaplan-Meier product-limit estimate.
Prognostic factors affecting survival were first identified by
univariate methods using the log rank test (Peto, 1977) with
analysis for trend where appropriate, and significant prog-
nostic factors were then subjected to multivariate analysis
using Cox's regression analysis.
Staging andfollow-up
All the tumours were classified by the latest TMN scheme
(UICC, 1988) and the patients performance status recorded
by Karnofsky's method. Histological assessment of the
degree of tumour differentiation was performed by one
pathologist (TRH). The patients have all been followed up
until death or within 6 weeks of the report if they are still
alive (median survival of 125 days). No patient has been lost
to follow-up.
Results
Ploidy
The coefficient of variation varied between 3.2 and 7.9
(median 6.4). Forty-seven (46%) of the tumours were
classified as diploid and 55 (54%) aneuploid. Of the 52
tumours from patients who received cisplatinum, 22 (42%)
were diploid and 30 (58%) were aneuploid. In the untreated
group 25 tumours (50%) were diploid and 25 (50%) were
aneuploid. The relationships between DNA content and sex,
age, performance status, site of the primary tumour, stage
grouping, histological grade and previous treatment are
shown in Tables I and II. There was no significant relation-
ship between any of these parameters and ploidy.
Chemotherapy
The mean number of courses of cisplatinum received by the
group of patients with diploid tumours was 2.5 and that by
the group with aneuploid tumours was 2.6
Relationship ofploidy to response
Twenty-two (40%) of the treated patients had a partial or
complete response to cisplatinum. Of the 22 diploid tumours,
eight (36%) patients showed a partial or complete response
compared with 14 of 30 (47%) aneuploid tumours. This
difference was not significant (X2 = 2.92) (Table III).
Relationship ofploidy to survival
The median survival of untreated patients with diploid
tumours was 74 days and of those with aneuploid tumours
55 days, but this difference did not reach statistical
significance (X2 = 1.72) (Figure 1). The median survival of
treated patients with aneuploid tumours was 224 days and
the increased survival of this treated group was significantly
longer than that for patients with untreated aneuloid cancers
(X2 = 20.7, P<0.001) (Figure 2). The median survival of
treated patients with diploid tumours was 118 days and this
was significantly longer than the median survival ofuntreated
patients with diploid tumours (X2 = 7.31, P<0.01) (Figure
3).
Prognosticfactors
Cox's regression analysis showed that age, sex, site ofdisease,
histological grading and previous treatment were not
significant prognostic factors. Karnofsky status and response
to chemotherapy were both highly significant predictors of
survival (P<0.001). An aneuploid tumour DNA content was
also found to be a significant predictor of survival
(P<0.025). Stage was not included in this analysis as most
tumours were in stage IV.
Table I Patient details: host factors
Untreated Treated
Diploid Aneuploid Diploid Aneuploid
Age (mean) 61.8 68.0 60.8 62.5
Sex M 15 16 16 22
F 10 9 6 8
Karnofsky status
Median 60 60 60 70
Range 20-90 20-80 30-80 40-70
Previous treatment
None 4 6 8 7
DXT/surgery 21 19 16 23
Table II Patients details: tumour factors
Untreated Treated
Diploid Aneuploid Diploid Aneuploid
Site
Mouth 3 10 5 7
Oropharynx 7 3 5 3
Hypopharynx 10 5 6 7
Larynx 1 5 5 9
Other 4 2 1 4
Disease stage
I 1 0 0 0
II 3 0 0 2
III 3 6 1 2
IV 18 19 21 26
Histological grade
Poor 12 14 14 20
Moderate 10 7 4 7
Well 3 4 4 3
Table III Response to treatment
Partial Complete
Progression No change response response
Diploid 10 4 7 1
Aneuploid 7 9 13 1
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Figure 1 Survival of untreated patients with diploid and aneu-
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Figure 2 Survival of treated and untreated patients with aneu-
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Figure 3 Survival of treated and untreated patients with diploid
tumours.
Discussion
Analysis of DNA content can provide important prognostic
information in a variety of malignant neoplasms. Abnormal
cellular DNA contents clearly worsen the prognosis in breast
carcinoma (Cornlisse et al., 1987), bronchial carcinoma
(Zimmerman et al., 1987), colorectal carcinoma (Armitage et
al., 1985), prostatic carcinoma (Fordham et al., 1986) and
squamous cell carcinoma at sites outside the head and neck,
such as the lung (Blondal, 1981) and cervix (Jakobsen, 1984).
Many of the increasing number of studies of squamous cell
carcinoma of the upper aerodigestive tract attempt only to
relate DNA content to clinical and pathological tumour
parameters, rather than to clinical outcome. In general there
has been no consistent relationship between ploidy or pro-
liferative characteristics and either pathological grade or
clinical stage.
No relationship was shown between ploidy and histological
grade by Kaplan et al. (1986), Johnson et al. (1985) and
Ensley et al. (1989) but the frequency of DNA non-diploid
tumours was found to correlate with a decrease in the histo-
logical grading by Holm (1982), Tytor et al. (1987) and
Feichter et al. (1987), who also found that it was directly
proportional to the percentage of cells in S-phase. We found
no correlation between the degree of histological different-
iation and DNA content. However, a parallel study of the
histopathology of these carcinomas has revealed other mor-
phological features which correlate with ploidy, diploid
carcinomas having prominent nucleoli and a lower surface
area to volume ratio of the groups of tumour cells (Helliwell
et al., 1989).
No significant relationship between ploidy and tumour
stage was found by Feichter et al. (1987), Holm (1982) and
Ensley et al. (1989), whereas Kaplan et al. (1986), Kokal et
al. (1988) and Tytor et al. (1989) reported a higher incidence
of aneuploidy in advanced tumours.
Data relating clinical outcome to DNA content in larger
series of patients treated in a uniform manner are few. Kokal
et al. (1988) studied a group of 76 patients with surgically
resectable lesions of the oral cavity, larynx and pharynx.
Those patients with aneuploid cancers had significantly lower
relapse-free and overall survival rates, and Cox's regression
analysis showed tumour DNA content to be an independent
prognostic factor. In surgically treated squamous cell carcin-
oma of the oesophagus a high hyperploid DNA content was
an independent prognostic factor indicating a poor prognosis
(Matsuura et al., 1986).
In a large series of oral cavity carcinomas (Tytor et al.,
1989), stage I and II aneuploid tumours had a worse prog-
nosis, but the reverse was true for stages III and IV which
were mostly treated by combined surgery and radiotherapy
or radiotherapy alone. A previous observation that aneuploid
tumours responded better to preoperative radiotherapy
(Franzen et al., 1986) was further confirmed in this later
study, and may account for the reversal of the prognosis for
those with stage III and IV aneuploid tumours. This finding
may also explain the report by Goldsmith et al. (1986) that,
among a heterogeneous group of patients with laryngeal
carcinoma, the aneuploid tumours had a better prognosis as
all but five of the 48 patients received radiotherapy as part of
their treatment. Franzen et al. (1986) also showed that the
mean S-phase value was higher (16.1%) in those tumours
that were eradicated by preoperative radiotherapy than for
those that did not respond (8.1%).
A strong direct correlation between the degree of DNA
aneuploidy and S-phase fraction has been reported for squa-
mous carcinomas of the head and neck (Ensley et al., 1989)
as well as a number of different solid tumours (Barlogie et
al., 1983). This suggests that aneuploid tumours may be
faster growing and therefore more susceptible to chemo-
therapy. In certain haematological malignancies treated by
chemotherapy, such as adults with acute myelogenous
leukaemia and children with acute lymphocytic leukaemia,
aneuploidy has emerged as a favourable prognostic factor
(Barlogie et al., 1987; Look et al., 1984). Similarly hyper-
diploid neuroblastomas in infants responded better to
chemotherapy than diploid tumours (Look et al., 1985).
Our results show a slightly longer median survival for
patients with diploid tumours compared with those with
aneuploid tumours receiving no further treatment. Paradoxi-
cally, response rates did not differ significantly between dip-
loid and aneuploid tumours but survival did. This is further
evidence of the unreliability of response in assessing the
efficacy of chemotherapy.
Diploid tumours may be less susceptible to cytotoxic
therapy, either because fewer cells are undergoing DNA
synthesis, or because of undefined characteristics confering
resistence that are independent of kinetic considerations.
Our data suggest that in end stage squamous cell car-
cinoma of the head and neck the aneuploid tumours are most
responsive to chemotherapy. In this study chemotherapy in-
creased survival for patients with diploid cancers by only 6
weeks, compared with an increase of 6 months for those with
aneuploid tumours. It is therefore doubtful whether cytotoxic
therapy for patients with diploid cancers is worthwhile. As
only 30-40% of these tumours responded to either single
agent or combination regimes, evaluation of DNA content
may aid in the selection of those patients who might benefit.762 L.D. COOKE et al.
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